Home » Topics » BioWorld Science

BioWorld Science
RSS

Novel tau tubulin kinase 1 inhibitors reduce tau phosphorylation in vivo

July 6, 2021

Venadaparib shows safety and preliminary efficacy in first-in-human trial

July 6, 2021

Mersana starts phase I/II umbrella study of XMT-1536 in high-grade serous ovarian cancer

July 6, 2021

Enrollment ongoing in phase I/II study of PVSRIPO

July 6, 2021

DPP3 is a marker of severity in heart failure

July 5, 2021

Transcenta reports antitumor responses with TST-001 in gastric cancer

July 5, 2021

Initiation of phase II study of HA-121-28 in advanced biliary tract cancer

July 5, 2021

SHR-1314 studied in phase II/III trial for active ankylosing spondylitis

July 5, 2021

Phase Ib data presented for ulixertinib plus palbociclib in advanced solid tumors

July 5, 2021

GNT-0003 restores UGT1A1 expression in patients with Crigler-Najjar syndrome

July 5, 2021

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...